Eva-Lotta Allan, an independent director, has >30 years of corporate, business development and operational experience from the biotechnology industry (private and public companies).
She is the Chair of C4X Discovery (C4XD.L) and of Draupnir Bio, Non-Executive Director of Almirall (BME:ALM) where she chairs the Nomination and Remuneration Committee. She is further a Non-Executive Board Director of Aleta BioTherapeutics, Crescendo Biologics and Targovax (TRVX).
In 2016 Eva-Lotta was elected to the Board of UK’s Bio Industry Association where she served as a board member for two years.
During her five years as Immunocore’s CBO she raised $320 million in a Series A round and established significant partnerships with top pharmaceutical companies. Eva-Lotta was previously at Ablynx, where she served as CBO for seven years participating in taking the company public and completed several structured complex partnerships with pharmaceutical companies. Eva-Lotta has also held a number of roles in biotech companies including as Senior Director Business Development and Site Operations (Europe) at Vertex Pharmaceuticals where she was also a member of the Vertex Limited Board.
She has a degree in microbiology and started her career at the Tumour biology department, Karolinska Institute in Stockholm and Omaha Nebraska Medical Center in Omaha.